Stool transplant added to infliximab or vedolizumab for ulcerative colitis
Tests a stool transplant added to standard drugs in adults with ulcerative colitis.
Key facts
- Who runs it
- Varsinais-Suomen hyvinvointialue
- Where
- Helsinki, Lahti, and Turku, FinlandSee the 3 sites
- Registry title
- Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 40 people, planned
- Started
- 1 Mar 2025
- Planned end
- 2 Mar 2026
- Type of study
- Interventional
- Record updated
- 21 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active ulcerative colitis who have never had biologic drugs and need to start one.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Active ulcerative colitis, or colitis that needs corticosteroids to stay controlled, with an indication for starting treatment with biological agents.
- Earlier treatment
- No earlier exposure to TNF blockers, vedolizumab or other biologics. No antibiotics or probiotics at the start.
Main reasons for not taking part
- Earlier treatment with infliximab, vedolizumab or other biologics
- Fulminant severe colitis (Truelove and Witts criteria)
- Pregnancy
- Known contraindication to infliximab or vedolizumab
- Impaired cognition, unable to give signed informed consent
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- 18-75 years old
- Active ulcerative colitis or corticosteroid dependent disease and an indication for induction therapy with biological agents
- Bionaive, i.e. no previous exposure to TNF blockers, vedolizumab or other biologics
- Signed informed consent
Who cannot take part
- Previous treatment with infliximab or vedolizumab or other biologics
- Antibiotic therapy at the baseline
- On-going probiotic medication
- Fulminant severe colitis (Truelove and Witts citeria)
- Pregnancy
- Known contraindication to infliximab or vedolizumab
- Impaired cognition and thus unable to provide signed informed consent
Where in Finland
- HUS-YhtymaeHelsinki, FinlandNot yet recruiting
- Paeijaet-Haemeen hyvinvointialueLahti, FinlandNot yet recruiting
- Varsinais-Suomen hyvinvointialueTurku, FinlandNot yet recruiting
About the trial
What the trial wants to find out
The main aim is to determine the feasibility to run a proper RCT with a larger sample size with fecal microbiota transplant (FMT) + infliximab (IFX) or FMT + vedolizumab (VDZ) since this study is a pilot study.
Read full original descriptionShow less
Objectives: To assess the efficacy of FMT + IFX as compared to IFX alone. To assess the efficacy of FMT + VDZ as compared to VDZ alone. To assess the safety of FMT in patients receiving biologics for active ulcerative colitis. To assess fecal microbiota changes in patients receiving biologics as compared to patients receiving biologics and FMT.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial
- Plain-language title
- Stool transplant added to infliximab or vedolizumab for ulcerative colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 21 January 2025